Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078152 · ClinicalTrials.gov registry record · Phase 4
Durvalumab Long-Term Safety and Efficacy Study
A Phase 4 study of Solid Tumor, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT04078152 is a Phase 4 study of Solid Tumor that has completed, run by AstraZeneca. The registered enrollment target is 163 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04078152, a Phase 4 study of Solid Tumor, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
Conditions Studied
Interventions
- DRUG Durvalumab
Study Locations (20)
Other
- Research Site - Rosario
- Research Site - Box Hill
- Research Site - Melbourne
- Research Site - Brussels
- Research Site - Kortrijk
- Research Site - Leuven
- Research Site - Florianópolis
- Research Site - Ijuí
North Carolina
- Research Site - Chapel Hill
- Research Site - Huntersville
California
- Research Site - Fullerton
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Augusta
Maryland
- Research Site - Baltimore
Minnesota
- Research Site - Minneapolis
Missouri
- Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04078152
The ClinicalTrials.gov registry entry for NCT04078152 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (26% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab is the first listed.
NCT04078152 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT04078152 about?
NCT04078152 is a clinical study titled "Durvalumab Long-Term Safety and Efficacy Study". The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
What is the current status of trial NCT04078152?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2019-09-05. Estimated completion is 2024-10-31.
What conditions does trial NCT04078152 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04078152?
The interventions under investigation include: Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04078152?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04078152 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.